Last $159.22 USD
Change Today +2.75 / 1.76%
Volume 782.2K
As of 6:40 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

perrigo co plc (PRGO) Key Developments

Perrigo Company plc Confirms First to File Patent Challenge for Generic Version of Aveed(R) (Testosterone Undecanoate) Injection

Perrigo Company plc announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application for testosterone undecanoate injection and that it has notified the owner of the Reference Listed Drug of its filing. Aveed(R) (testosterone undecanoate) injection is a schedule II controlled substance indicated for testosterone replacement therapy in adult males for the conditions associated with a deficiency or absence of endogenous testosterone of primary hypogonadism (congenital or acquired) or hypogonadotropic hypogonadism (congenital or acquired).

Perrigo Company plc Launches Generic Version Of Protopic(R) Ointment 0.1% And 0.03%

Perrigo Company plc announced that it has agreed to market the authorized generic version of Astellas U.S. LLC's' Protopic(R) Ointment 0.1% and 0.03%. Shipments to the company's pharmacy customers have commenced. Protopic(R) Ointment (tacrolimus) is indicated to treat moderate to severe eczema.

Endo Pharmaceuticals Solutions Inc., Bayer Intellectual Property GmbH and Bayer Pharma AG File Suit Against Perrigo Company plc in the United States District Court for the District of Delaware, Alleging Patent Infringement

Perrigo Company plc announced that it has filed with the U.S. Food and Drug Administration an Abbreviated New Drug Application for testosterone undecanoate injection and that it has notified the owner of the Reference Listed Drug of its filing. On November 20, Endo Pharmaceuticals Solutions Inc., Bayer Intellectual Property GmbH and Bayer Pharma AG filed suit against Perrigo in the United States District Court for the District of Delaware, alleging patent infringement. The action formally initiates the process under the Hatch-Waxman Act. Perrigo confirms that it is a first filer for this opportunity, entitling it to 180 days of generic exclusivity.

Perrigo Company Public Limited Company Announces Consolidated Earnings Results for the First Quarter Ended September 27, 2014; Provides Earnings Guidance for the Fiscal 2015

Perrigo Company Public Limited Company announced consolidated earnings results for the first quarter ended September 27, 2014. For the quarter, the company reported net sales of $951.5 million compared to $933.4 million a year ago. Operating income was $137.2 million compared to $179.7 million a year ago. Income before income taxes was $108.6 million compared to $157.3 million a year ago. Net income was $96.3 million compared to $111.4 million a year ago. Basic and diluted EPS was $0.72 compared to $1.18 a year ago. Net cash from operating activities was $195.1 million compared to $98.7 million a year ago. Additions to property and equipment were $31.7 million compared to $40.4 million a year ago. Adjusted operating income was $247.3 million compared to $226.2 million a year ago. Adjusted income before income taxes was $220.6 million compared to $206.5 million a year ago. Adjusted net income was $187.5 million or $1.40 per diluted share compared to $143.9 million or $1.52 per diluted share a year ago. For the fiscal year 2015, the company expects diluted EPS in the range from $4.58 to $4.88, adjusted diluted EPS in the range from $7.20 to $7.50.

Perrigo Company plc Declares Quarterly Dividend, Payable on December 16, 2014

Perrigo Company plc announced that its board of directors declared a quarterly dividend of $0.105 per share, payable on December 16, 2014 to shareholders of record on November 28, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRGO:US $159.22 USD +2.75

PRGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $72.41 USD +0.19
Hospira Inc $60.29 USD +0.21
Mallinckrodt PLC $91.64 USD +0.73
Mead Johnson Nutrition Co $103.41 USD +2.02
Mylan Inc/PA $58.62 USD +2.45
View Industry Companies
 

Industry Analysis

PRGO

Industry Average

Valuation PRGO Industry Range
Price/Earnings 100.0x
Price/Sales 5.2x
Price/Book 2.4x
Price/Cash Flow 110.5x
TEV/Sales 4.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PERRIGO CO PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.